Skip to main content
Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc. — Investor Relations & Filings

Ticker · TPST ISIN · US69014Q1013 US Professional, scientific and technical activities
Filings indexed 984 across all filing types
Latest filing 2024-01-05 Director's Dealing
Country US United States of America
Listing US TPST

About Tempest Therapeutics, Inc.

https://www.tempesttx.com/

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates and cell therapies. The company develops first-in-class therapeutics that combine tumor-targeted and immune-mediated mechanisms to treat cancer. Its lead product candidate is amezalpat (TPST-1120), an oral, selective PPARα antagonist being evaluated in a global, randomized combination study for hepatocellular carcinoma. In addition to its small molecule platform, the company is also developing dual-chimeric antigen receptor (CAR) T-cell programs.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2024-01-05 English
FORM 4 SUBMISSION
Director's Dealing
2024-01-05 English
S-8 POS
Regulatory Filings
2023-11-17 English
S-8 POS
Regulatory Filings
2023-11-17 English
S-8 POS
Regulatory Filings
2023-11-17 English
S-8 POS
Regulatory Filings
2023-11-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.